Friday, July 10, 2026

pharma · Breast Cancer · Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

Hoffmann-La Roche is a pharma organization headquartered in Basel, CH. Primary therapeutic focus areas include Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Non-Small Cell Lung Cancer, Solid Tumo

Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
286
Drugs
212
Patents
0
Clinical program

WC45725

Phase 3 · small molecule · Obesity or Overweight Without Type 2 Diabetes

WC45725 for Obesity or Overweight Without Type 2 Diabetes is a Phase 3 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).

← All Hoffmann-La Roche projects Phase 3 small molecule active

Internal code WC45725

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Hoffmann-La Roche
Phase
Phase 3
Modality
small_molecule
Indication
Obesity or Overweight Without Type 2 Diabetes
Status
active
Trials
1

Clinical trials